Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) PT at $25.57

Key Points

• Stoke Therapeutics has received a consensus recommendation of "Buy" from nine ratings firms, with seven analysts rating it as a buy and two as a strong buy.
• The average twelve-month price target set by brokerages for Stoke Therapeutics is $25.57, with some firms suggesting a target as high as $30.00.
• The company recently reported a net margin of 26.25% and earnings per share of ($0.40), which surpassed analysts' expectations by $0.17.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) has received a consensus recommendation of "Buy" from the nine ratings firms that are covering the stock, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $25.5714.

Several equities analysts recently issued reports on the company. Wedbush increased their target price on Stoke Therapeutics from $16.00 to $22.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 13th. BTIG Research set a $28.00 target price on Stoke Therapeutics and gave the stock a "buy" rating in a research note on Monday, August 18th. Needham & Company LLC reissued a "buy" rating and set a $22.00 target price on shares of Stoke Therapeutics in a research note on Tuesday, July 1st. Jefferies Financial Group assumed coverage on Stoke Therapeutics in a research note on Friday, July 18th. They set a "buy" rating and a $30.00 target price on the stock. Finally, Chardan Capital reissued a "buy" rating and set a $24.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, August 13th.

Insider Buying and Selling

In related news, insider Barry Ticho sold 5,501 shares of the stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $19.87, for a total transaction of $109,304.87. Following the transaction, the insider owned 18,469 shares of the company's stock, valued at approximately $366,979.03. This represents a 22.95% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward M. Md Kaye sold 45,996 shares of the stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $20.13, for a total value of $925,899.48. Following the completion of the sale, the director directly owned 91,585 shares in the company, valued at $1,843,606.05. This represents a 33.43% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 107,719 shares of company stock valued at $2,063,359. Corporate insiders own 9.50% of the company's stock.

Institutional Investors Weigh In On Stoke Therapeutics

Hedge funds have recently bought and sold shares of the stock. BNP Paribas Financial Markets raised its position in Stoke Therapeutics by 66.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company's stock valued at $48,000 after purchasing an additional 1,668 shares in the last quarter. Tower Research Capital LLC TRC raised its position in Stoke Therapeutics by 461.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company's stock valued at $50,000 after purchasing an additional 3,591 shares in the last quarter. GAMMA Investing LLC raised its position in Stoke Therapeutics by 1,842.0% in the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock valued at $36,000 after purchasing an additional 5,084 shares in the last quarter. Osaic Holdings Inc. raised its position in Stoke Therapeutics by 263.3% in the 2nd quarter. Osaic Holdings Inc. now owns 7,488 shares of the company's stock valued at $85,000 after purchasing an additional 5,427 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey raised its position in Stoke Therapeutics by 33.2% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 9,558 shares of the company's stock valued at $108,000 after purchasing an additional 2,384 shares in the last quarter.

Stoke Therapeutics Stock Performance

Shares of Stoke Therapeutics stock traded up $0.76 during trading hours on Friday, hitting $23.50. The company's stock had a trading volume of 840,578 shares, compared to its average volume of 870,077. Stoke Therapeutics has a twelve month low of $5.35 and a twelve month high of $24.60. The firm has a fifty day moving average of $16.95 and a 200-day moving average of $11.94. The stock has a market cap of $1.29 billion, a price-to-earnings ratio of 27.65 and a beta of 1.14.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.17. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%.The business had revenue of $13.82 million for the quarter, compared to analyst estimates of $31.51 million. On average, sell-side analysts expect that Stoke Therapeutics will post -2.01 earnings per share for the current fiscal year.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.